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Background: Balloon aortic valvuloplasty (BAV) has often a compassionate rule in
the treatment of symptomatic and severe aortic stenosis (AS). Aim of this work was to
evaluate the clinical outcomes of BAV performed in emergency clinical setting.
Methods: Between September 2007 and September 2012, forty-two consecutive
emergency BAV were performed because of severe AS symptomatic for refractory
pulmonary edema (71%) or cardiogenic shock (29%).
Results: Most of the patients were female (60%) with mean age of 865 years and
Logistic Euroscore I of 4021%. Baseline echocardiographic data showed an aortic
valve area of 0.51.4 cm2 and a mean transvalvular gradient of 4614 mmHg, high
pulmonary hypertension (5015 mmHg) and left ventricular ejection fraction of
4114%. Coronary artery disease was present in 52%, with multivessel disease in
24% of the cases. During BAV, a coronary revascularization was performed in 26% of
the pts. An undersized balloon (20 mm) was used in 71% of cases. Drop of 3320
mmHg of peak aortic gradient was observed after BAV and in 57% of the procedures
one balloon inﬂation was enough. In-hospital death rate was 28%. All-cause death at 6
months was 45%. Transcatheter aortic valve replacement (TAVR) was performed in
56% of survival pts with a signiﬁcant improvement in clinical outcomes (NYHA class
II and no mortality at 6 months follow up in all pts).
Conclusions: Although high mortality rate was observed after BAV in emergency
clinical setting (refractory pulmonary edema or cardiogenic shock due to severe AS)
survival pts had a chance to be able to complete the treatment of AS by TAVR
procedure.
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Background: BNP is synthesized in cardiac ventricular tissue in response to increased
wall stress and is known to be elevated in patients with aortic stenosis, especially those
with clinical heart failure. We sought to characterize the timing and prognostic
signiﬁcance of changes in BNP levels after TAVR in the PARTNER I trial.
Methods: A total of 801 patients treated with transfemoral (TF) TAVR had BNP
levels determined at baseline, 1w, 6 m, 12 m, and 24 m after therapy. We further
divided patients into Group I (those with rising BNP levels at 1m) and Group II (those
with stable or falling BNP).
Results:Median Baseline BNP [IQR] was 619 [293, 1438], falling to 610 [289, 1342]
at 1w and 479 [238, 1006] at 1m. Thereafter, BNP levels remained stable at 6m (357
[175, 827]), 1y (341 [176, 729]), and 2y (346 [187, 782]). Mortality was increased at
6m, 1y, and 2y for patients with rising BNP (See ﬁgure). Similarly, repeat hospital-
ization was higher at 6m (18 vs 10%, p¼0.0008), 1y (24 vs 13%, p¼0.0002), and 2y
(40 vs 31%, p¼0.006). Patients in Group I were more likely to have moderate/severe
AR post-procedure (14.7 vs 9.3%, p¼0.03596). Moderate or severe mitral regurgi-
tation was similar between Group I and Group II at 1m echo (24 vs 18%, respectively,
p¼0.08), but was more common in Group I patients on the 6m echo (25 vs 16%,
p¼0.02).
Conclusions: BNP levels are elevated and tend to fall rapidly after TF-TAVR. Rising
BNP levels after TAVR are associated with a signiﬁcantly increased risk of death or
rehospitalization and post-procedure moderate/severe AR.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-774
Circulatory Support is Associated with Higher Mortality During TAVR
Satya S. Shreenivas1, Scott M. Lilly2, Wilson Y. Szeto3, Nimesh Desai4,
Saif Anwaruddin2, Joseph E. Bavaria2, Vinod Thourani5, Raj Makkar6,
Augusto Pichard7, Webb John8, Todd Dewey9, Samir Kapadia10, Ke Xu11,
Martin Leon11, Howard C. Herrmann12
1Hospital of The University of Pennsylvania, Philadelphia, PA, 2Hospital of the
University of Pennsylvania, Philadelphia, PA, 3University of Pennsylvania Medical
Center, Philadelphia, Pennsylvania, 4Penn Medicine, Philadelphia, PA, 5Emory
University, Atlanta, GA, 6Associate Prof, UCLA school of Medicine, Los Angeles,
California, 7washsington hospital center, Washington, United States, 8St Pauls
Hospital, vancouver, british Columbia, 9Medical City Dallas Hospital, Dallas, TX,
10Cleveland Clinic, Cleveland, United States, 11Cardiovascular Research Foundation,
New York, NY, 12Hospital of the University of Pennsylvania, Philadelphia,
Pennsylvania
Background: Circulatory support (CS) may be needed during TAVR, but little is
known about the incidence, outcomes, and predictors of its use.
Methods: The study population included all patients in the PARTNER trial and
Continued Access Registry (CAR) that underwent TAVR. Patients that received CS
(intra-aortic balloon pump [IABP] or cardiopulmonary bypass [CPB]), either elective
pre-procedure or urgent intra-procedure, were compared to patients that did not
receive CS.
Results: Of the 2538 patients, 203 (8%) received support, including CPB (n¼133,
66%) or IABP (n¼70, 34%). Compared to those not receiving support, patients
receiving CS were more likely male (64% vs 51%, p< 0.0001), undergo transapical
access (81% vs 39%, p<0.0001), have prior CABG (60% vs 41%, p < 0.0001), lower
left ventricular EF (47 vs 53%, p<0.001), and moderate or severe mitral regurgitation
(28% vs 21%, p ¼ 0.03). The incidence of CS was higher in the CAR than in the
PARTNER trial (9% vs 5%), partly due to an increased proportion of transapical cases
(50% vs 20%, respectively). The use of circulatory support was associated with
greater procedural complications, including major vascular complications (17% vs
5%, p< 0.0001) and valve embolization (5% vs 0.5%, p<0.0001). CS was associated
with a signiﬁcantly higher 30 day all-cause mortality (25% vs 5%, p< 0.0001), and
was higher in patients that received CPB compared to IABP (32% vs 13%, p¼0.003).
The mortality difference between the CS and non-CS groups persisted at two years
(48% vs 28%, p< 0.0001). The speciﬁc indication for CS, elective pre-procedure or
urgent resulting from a complication, will be separately analyzed to determine the
effect on outcome.
Conclusions: The use of CS during TAVR is surprisingly frequent, associated with
procedural complications, and portends a higher early and late mortality. CS was used
more frequently in registry patients as compared to randomized trial patients. Iden-
tifying patients most likely to beneﬁt from CS may represent an opportunity to
improve outcomes.
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Background: Transcatheter aortic valve replacement (TAVR) can be performed via
different access routes and settings. The economic beneﬁts of TAVR over SAVR in
a variety of procedural settings are unclear. Our goal was to compare cost of TAVR byacts/POSTER/Aortic Valve Disease and Treatment B235
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Stransfemoral (TF) route in the catheterization laboratory (C-TF) or hybrid room
(OR-TF) and OR non-TF TAVR.
Methods: A retrospective study was performed on 174 patients who underwent
TAVR at a single US academic institution using the SAPIEN valve from 11/2011 to 4/
2013. Patients were stratiﬁed into 3 groups: C-TF TAVR (n¼51), OR-TF TAVR
(n¼39), and OR-non-TF TAVR (n¼84). All C-TF patients were performed with i.v.
sedation and TTE. The OR-TF and OR-non-TF patients were performed in the hybrid
OR with general anesthesia and TEE. Total variable cost, hospital payment, and
contribution margin were utilized to determine the ﬁnancial viability of TAVR.
Results: Compared to OR-TF and OR-non-TF, C-TF had a signiﬁcantly lower
procedure time (p<0.001) and postop ventilator hours (p<0.001). Resource utilization
in terms of ICU (p<0.001), postop (p<0.001), and total hospital LOS (p<0.001) was
signiﬁcantly higher in OR-non-TF patients. Total variable cost in the OR-non-TF
TAVR was the highest ($57,19723,142), but hospital payment was comparably the
highest ($62,64758,826); leading to the highest contribution margin
($19,59443,553). Total variable cost and hospital payment were lowest in the C-TF
group, leading to a contribution margin of $15,52919,556 (Table).30 days
p-value
1 year *
p-value
< 90 years  90 years < 90 years  90 years
no of pacients (%) no patients (%)
All cause-
death
8.4% 10.4% 0.59 18.9 18.8% 0.87
Cardiovascular
death
7% 6.2% 0.99 12.4% 10.4% 0.64
Stroke 3.8% 4.2% 0.70 5.4% 8.3% 0.52
Death/
stroke
8.6% 8.3% 0.99 21.9% 27.1% 0.46
Major
bleeding
16.5% 10.4% 0.28 17.6% 10.4% 0.21
Safety
endpoint**
21.6% 20.8% 0.90 - - -
All clinical events were adjudicated according to VARC-2 criteria.
* Kaplan-Meier estimates .
** Composite of death, stroke, major bleeding, renal insufﬁciency, major vascular
complication, re-intervention or repeat surgery.
Table. Admission Resource Use and Costs
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OR time, min 160  85 229  70 234  49 <0.001
Ventilator hours 1.7  10.1 23.4  66.7 48.4  131.0 <0.001
ICU LOS, hrs 21.9  17.7 50.5  64.1 98.3  138.2 <0.001
Post-op LOS, days 3.7  2.7 4.7  3.2 9.1  7.5 <0.001
Total hospital LOS 6.0  4.9 7.1  5.7 11.2  8.5 <0.001
Total variable
cost
$45,173 
16,988
$52,268 
16,480
$57,197 
23,142
<0.001
Hospital payment $45,412 
28,158
$59,931 
20,954
$62,647 
58,826
0.002
Contribution
margin
$15,529 
19,556
$10,421 
20,389
$19,594 
43,553
0.27
All values are meanSD; all cost data is in $US.Conclusions: This is the ﬁrst study comparing the economic impact of the minimalist
and standard approaches to TAVR. The economic beneﬁts of TAVR in all groups
were shown to be ﬁnancially viable (positive contribution margin). Resource utili-
zation was the least in the C-TF group, but hospital reimbursement was also the
lowest. A more deﬁned reimbursement strategy for these high-risk patients is required.
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Background: Trans-femoral (TF) approach represents the ﬁrst choice of vascular
access for transcatheter aortic valve replacement (TAVR). When not feasible, alter-
native approaches such as axillary artery (TA) or, more recently, direct ascending
aorta (DA) are used for self-expandable valve implantation. Aim of this work was to
evaluate the safety of TAVR with self-expandable valve through these alternative
vascular approaches in  85 years old patients (pts).
Methods: From the Clinical Service (former Italian CoreValve Registry) dataset,
1317 consecutive pts underwent TAVR with 3 generation CoreValve in 7 Italian sites
between June 2007 and November 2012, were included in this analysis. Pts were
divided into two groups according to the vascular access: TF or alternative approaches
(TA and DA). Primary end point was the 30-day safety evaluation according to
VARC-2 criteria.
Results: Four hundred and eighty-four pts (37%) had an age  85 years (range,
85-99). TF access was used in 81% and alternative approaches in 19% of cases (16%
TA and 2.5% DA). Sex female was higher in TF (64% vs 50%, respectively, p¼0.014)
while the Logistic Euroscore I was higher in the second group (21% vs 26%,B236 JACC Vol 62/18/Suppl B j October 27–Novemberrespectively, p¼0.039), as well as the presence of coronary artery disease (41% vs
58%, p¼0.004) and history of myocardial infarction (14% vs 23%, respectively,
p¼0.036). There was non signiﬁcant difference regarding to devices success between
two approaches (95% vs 96%, respectively, p¼0.8). Combined early safety end point
was similar between two groups (28% vs 22%, respectively, p¼0.23), as well as the
individual components, except for a signiﬁcant higher incidence of acute kidney injury
(stage II- III) in TF compared to alternative accesses (30% vs 17%, respectively,
p¼0.010). All-cause of death and cardiovascular death at 30 days and 1 year of follow
up were similar into two groups irrespective of different type of vascular access.
Conclusions: When TF approach was not feasible because of anatomical reasons, the
alternative approach such as axillary artery (TA) or, more recently, direct ascending
aorta (DA) could lead to a self-expandable valve implantation safely also in elderly
patients.
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Background: Transcatheter aortic valve implantation (TAVI) has been established as
a standard treatment in inoperable and high-risk elderly pts with severe aortic stenosis.
However, there is no data thus far assessing the safety and the efﬁcacy of TAVI in pts
older than 90 years. We therefore sought to evaluate the early- and long-term clinical
outcomes in nonagenarian pts undergoing TAVI.
Methods: Between January 2008 and February 2013, pts with symptomatic severe
aortic stenosis underwent and were enrolled in the Brazilian multicenter registry.
Among a total of 418 pts, 370 were < 90 years and 48 (13%) were nonagenarian.
Results: Nonagenarian pts were 12 years older than pts < 90 years (92.4 years vs.
80.12 years; p<0.001). Compared with pts < 90 years, nonagenarian pts had higher
STS risk score (19.4413.84% vs. 14.0312.38%; p¼0.005), lower body mass index
(24.553.40 vs. 26.314.61 kg/m2; p¼0.01), but higher baseline left ventricular
ejection fraction (61.7412.32% vs. 57.27%15.60%, p¼0.03). 30-day and 1-year
main clinical outcomes are presented in Table.Conclusions: In this real world Brazilian registry, nonagenarian pts who underwent
TAVI had favorable and similar early- and long-term clinical outcomes as compared
with pts < 90 years. The treatment of symptomatic severe aortic stenosis in nona-
genarians pts with TAVI deemed to be a non-futility approach.1, 2013 j TCT Abstracts/POSTER/Aortic Valve Disease and Treatment
